197 related articles for article (PubMed ID: 29748373)
1. slan
Vermi W; Micheletti A; Finotti G; Tecchio C; Calzetti F; Costa S; Bugatti M; Calza S; Agostinelli C; Pileri S; Balzarini P; Tucci A; Rossi G; Furlani L; Todeschini G; Zamò A; Facchetti F; Lorenzi L; Lonardi S; Cassatella MA
Cancer Res; 2018 Jul; 78(13):3544-3559. PubMed ID: 29748373
[TBL] [Abstract][Full Text] [Related]
2. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.
Vari F; Arpon D; Keane C; Hertzberg MS; Talaulikar D; Jain S; Cui Q; Han E; Tobin J; Bird R; Cross D; Hernandez A; Gould C; Birch S; Gandhi MK
Blood; 2018 Apr; 131(16):1809-1819. PubMed ID: 29449276
[TBL] [Abstract][Full Text] [Related]
3. slan+ Monocytes Kill Cancer Cells Coated in Therapeutic Antibody by Trogoptosis.
Finotti G; Pietronigro E; Balanzin C; Lonardi S; Constantin G; Chao MP; Tecchio C; Vermi W; Cassatella MA
Cancer Immunol Res; 2023 Nov; 11(11):1538-1552. PubMed ID: 37695535
[TBL] [Abstract][Full Text] [Related]
4. Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.
Nakamura K; Casey M; Oey H; Vari F; Stagg J; Gandhi MK; Smyth MJ
Leukemia; 2020 Oct; 34(10):2708-2721. PubMed ID: 32269319
[TBL] [Abstract][Full Text] [Related]
5. Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity.
Neumann F; Acker F; Schormann C; Pfreundschuh M; Bittenbring JT
Cancer Immunol Immunother; 2018 Nov; 67(11):1709-1718. PubMed ID: 30132083
[TBL] [Abstract][Full Text] [Related]
6. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab.
Matsuki E; Bohn OL; El Jamal S; Pichardo JD; Zelenetz AD; Younes A; Teruya-Feldstein J
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):572-580. PubMed ID: 30106758
[TBL] [Abstract][Full Text] [Related]
8. Developing a 3D B Cell Lymphoma Culture System to Model Antibody Therapy.
Foxall R; Narang P; Glaysher B; Hub E; Teal E; Coles MC; Ashton-Key M; Beers SA; Cragg MS
Front Immunol; 2020; 11():605231. PubMed ID: 33628205
[TBL] [Abstract][Full Text] [Related]
9. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
10. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
[TBL] [Abstract][Full Text] [Related]
11. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
Decaup E; Rossi C; Gravelle P; Laurent C; Bordenave J; Tosolini M; Tourette A; Perrial E; Dumontet C; Poupot M; Klein C; Savina A; Fournié JJ; Bezombes C
Front Immunol; 2019; 10():1943. PubMed ID: 31475004
[TBL] [Abstract][Full Text] [Related]
12. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
Front Immunol; 2019; 10():562. PubMed ID: 30984171
[TBL] [Abstract][Full Text] [Related]
13. CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169- monocyte-derived cells in diffuse large B-cell lymphomas.
Marmey B; Boix C; Barbaroux JB; Dieu-Nosjean MC; Diebold J; Audouin J; Fridman WH; Mueller CG; Molina TJ
Hum Pathol; 2006 Jan; 37(1):68-77. PubMed ID: 16360418
[TBL] [Abstract][Full Text] [Related]
14. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.
Pavlasova G; Borsky M; Svobodova V; Oppelt J; Cerna K; Novotna J; Seda V; Fojtova M; Fajkus J; Brychtova Y; Doubek M; Pospisilova S; Mayer J; Mraz M
Leukemia; 2018 Sep; 32(9):2028-2031. PubMed ID: 30030508
[No Abstract] [Full Text] [Related]
15. Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma.
Le Gallou S; Lhomme F; Irish JM; Mingam A; Pangault C; Monvoisin C; Ferrant J; Azzaoui I; Rossille D; Bouabdallah K; Damaj G; Cartron G; Godmer P; Le Gouill S; Casasnovas RO; Molina TJ; Houot R; Lamy T; Tarte K; Fest T; Roussel M
Front Immunol; 2021; 12():755623. PubMed ID: 34975843
[TBL] [Abstract][Full Text] [Related]
16. Deciphering the fate of slan
Bianchetto-Aguilera F; Tamassia N; Gasperini S; Calzetti F; Finotti G; Gardiman E; Montioli R; Bresciani D; Vermi W; Cassatella MA
FASEB J; 2020 Jul; 34(7):9269-9284. PubMed ID: 32413173
[TBL] [Abstract][Full Text] [Related]
17. T cells, particularly activated CD4
Wang Z; Chimenti MS; Strouse C; Weiner GJ
Cancer Immunol Immunother; 2022 Feb; 71(2):237-249. PubMed ID: 34110453
[TBL] [Abstract][Full Text] [Related]
18. Potential contribution of tumor-associated slan
Lonardi S; Licini S; Micheletti A; Finotti G; Vermi W; Cassatella MA
J Leukoc Biol; 2018 Mar; 103(3):559-564. PubMed ID: 28951423
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
[TBL] [Abstract][Full Text] [Related]
20. Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.
VanDerMeid KR; Elliott MR; Baran AM; Barr PM; Chu CC; Zent CS
Cancer Immunol Res; 2018 Oct; 6(10):1150-1160. PubMed ID: 30089638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]